Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes

A Complex comprised of a VEGF Nucleic Acid Ligand comprising 2′F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound.

A method for treating a VEGF mediated disease or medical condition comprising administering a pharmaceutically effective amount of a Complex comprised of a VEGF Nucleic Acid Ligand comprising 2′F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Compound or a Lipophilic Compound.

A method for improving the pharmacokinetic properties of a VEGF Nucleic Acid Ligand comprising 2′F-modified nucleotides comprising:

• covalently linking said VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a I o Complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound;
• and administering said Complex to a patient.

A method for targeting a therapeutic or diagnostic agent to a specific predetermined biological target that is expressing VEGF in a patient comprising:

• covalently linking said therapeutic or diagnostic agent with a Complex comprised of a VEGF Nucleic Acid Ligand comprising 2′F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound, and administering said Complex to a patient.

A method of inhibiting VEGF mediated angiogenesis comprising:

• covalently linking a VEGF Nucleic Acid ligand comprising 2′F-modified nucleotides to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex;
• and administering said Complex to a patient.

A method of inhibiting the growth of tumors comprising:

• covalently linking a VEGF Nucleic Acid Ligand comprising 2′F-modified nucleotides to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex;
• and administering said Complex to a patient.

A method of inhibiting macular degeneration comprising:

• covalently linking a VEGF Nucleic Acid Ligand comprising 2′F-modified nucleotides to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex;
• and administering said Complex to a patient.

A method for prolonging the residence time of a Nucleic Acid Ligand in an ocular application comprising attaching a Non-Immunogenic, High Molecular Weight Compound to a Nucleic Acid Ligand to form a Complex, and administering said complex to the eye.